Introduction
============

Chordomas are rare primary bone neoplasms that typically originate from the spine or skull base. Conventional practice generally involves maximal safe surgical removal, often followed by focused radiation therapy. Despite this, many patients ultimately succumb to local treatment failure and recurrence. To date, no chemotherapeutic agent has demonstrated sufficient efficacy to constitute part of the first-line therapy for these locally aggressive neoplasms. Progress in the understanding of chordomas' molecular pathogenesis has given rise to efforts to treat chordomas with targeted therapies. This article provides an essential review on cranial base chordomas, outlines current surgery and radiation-treatment paradigms, and further examines how the evolving understanding of molecular pathogenesis has informed potential new targeted chemotherapeutic approaches.

Description and epidemiology
============================

Chordomas are rare neoplasms, occurring with an annual age-adjusted incidence of 0.02 per 100,000 person-years, and account for 1%--4% of all primary malignant bone tumors.[@b1-tcrm-11-873],[@b2-tcrm-11-873] Arising from embryonic notochord remnants, chordomas occur at any point along the skeletal neuraxis,[@b2-tcrm-11-873],[@b3-tcrm-11-873] with the sacrum and cranial base being the most frequently affected areas.[@b4-tcrm-11-873] Cranial base chordomas account for 35%--49% of all chordomas.[@b3-tcrm-11-873] Consistent with their site of origin, chordomas predominantly present in the extradural space and produce symptoms secondary to local growth and bony destruction. Of note, chordomas can rarely present as a solitary intradural lesion in the retroclival space, and while they behave in similar fashion to their classic extradural counterparts,[@b5-tcrm-11-873] intradural lesions must be distinguished from a more benign variant of intradural notochordal tumor termed *ecchordosis physaliphora*, which can have very subtle radiologic and pathologic differences from more malignant chordomas.[@b6-tcrm-11-873],[@b7-tcrm-11-873]

The median age at presentation for cranial chordomas is in the sixth decade, slightly younger for sacral chordomas,[@b2-tcrm-11-873] and with rare occurrences in the pediatric population.[@b2-tcrm-11-873],[@b8-tcrm-11-873] Given the predilection for growth in the clivus and cavernous sinus regions, the most frequent clinical presentations of skull-base chordomas are cranial nerve deficits (eg, abducens or oculomotor nerve palsy).[@b9-tcrm-11-873]

The median survival of cranial base chordomas is estimated at 6.29 years,[@b4-tcrm-11-873],[@b10-tcrm-11-873] with 5-year overall survival (OS) and progression-free survival (PFS) rates of 78.4% and 50.8%, respectively.[@b11-tcrm-11-873] The lethality of skull-base chordoma is largely due to local progression, although systemic metastasis has been reported in 12.5% of skull base/craniocervical tumors.[@b12-tcrm-11-873] A large retrospective study of cranial chordomas recently suggested a trend toward improvement in survival over time,[@b3-tcrm-11-873] with 5-year OS for the 1975--1984, 1985--1994, and 1995--2004 epochs of 48.5%, 73.0%, and 80.7%, respectively. The reasons for such improvements are unclear, but may reflect earlier detection and treatment (lead-time bias); better treatment modalities, including the addition of endoscopic approaches both as an adjunct to open procedures and as a standalone procedure, especially for midline clival tumors; refinements in the safety of open skull-base approaches; and use of greater sophistication in radiation therapy-delivery techniques, allowing for safer prescription of the requisite higher dose for chordomas.

Current treatment paradigm for skull-base chordomas
===================================================

There is no uniform consensus regarding the optimal standard treatment for skull-base chordomas, and evidence regarding various paradigms stem from retrospective series over often long and inconsistent treatment eras. While it is generally agreed that a maximal safe removal of the tumor should be done first,[@b13-tcrm-11-873] a number of other practice differences exist, including the type of radiation therapy, the indications for radiation therapy (eg, after complete vs only incomplete resection; upfront or at the time of recurrence), and the management of metastases. To date, no chemotherapeutic agent have been approved for the first-line treatment of skull-base chordomas.[@b14-tcrm-11-873] At the time of recurrence, the respective roles of repeat resection, radiation therapy, and chemotherapy remain unclear.

Surgery
-------

The principal goals of surgery beyond histologic confirmation of the lesion are to achieve a maximal safe resection, provide symptomatic improvement, and to facilitate adjuvant treatment, such as radiotherapy, by minimizing the treatment volume and maximizing the distance between the target volume and critical surrounding neurovascular structures. In the skull base, surgical resection of chordomas remains a challenge, due to anatomic constraints in accessing the skull base, as well as their locally aggressive growth pattern and involvement of surrounding neurological structures, such as the brain stem, cranial nerves, and internal carotid and/or vertebral arteries. These factors often exceed the ability of any single surgical approach to achieve maximal resection, thus necessitating complex combined or multiple approaches. Understandably, the majority of surgical series describe a practice of piecemeal intralesional resection to normal dural and/or bony margins, as opposed to en bloc resection with margins as described for their sacral counterparts.[@b15-tcrm-11-873]

Despite these limitations, the literature supports the benefit of surgical resection on survival for chordomas. In a large review of 962 patients with spinal, sacral, or cranial base chordomas identified from the Surveillance, Epidemiology, and End Results (SEER) database, Jawad and Scully found surgical resection to be an independent predictor of OS.[@b16-tcrm-11-873] In addition, in a meta-analysis of 23 retrospective studies, 807 patients with cranial base chordomas were analyzed together, with a mean follow-up of 53.6 months.[@b11-tcrm-11-873] The rate of complete resection ranged widely across studies, from 0% to 73.7%. Those patients with a complete resection had a 5-year OS of 95% (vs 71% without) and 5-year PFS of 87% (vs 50% without). Despite a seemingly clear benefit of complete resection in this study, a few stipulations should be mentioned. The majority of included studies reported the routine use of adjuvant radiotherapy, including after complete resection. Most outcomes reported were for patients who had undergone open resection, with only a small minority of cases undergoing endoscopic endonasal resection. The careful assessment of a complete resection can be difficult, and may have differed across studies. For example, a complete resection may refer to the soft-tissue component of the tumor, versus a resection of the tumor and all affected surrounding bone and dura.

To achieve maximal resection, traditional open skull-base approaches (summarized elsewhere)[@b17-tcrm-11-873],[@b18-tcrm-11-873] are most commonly used, but the less invasive endoscopic approaches have been increasingly adopted. The endoscope has been employed as an adjunct to open resection or as a standalone endonasal approach to resect midline skull-base chordomas.[@b13-tcrm-11-873],[@b19-tcrm-11-873]--[@b27-tcrm-11-873] Advances in such techniques as pituitary gland mobilization, posterior clinoidectomy, and skeletonization of the petrous carotid arteries have permitted access to the entire rostrocaudal extent of the clivus via this approach.[@b28-tcrm-11-873] However, comparisons of endoscopic versus microscopic resection of cranial base chordomas are invariably prone to selection bias, and understandably long-term comparisons of the rate of complete resection, recurrence, and OS have to date not been published. In one systematic review,[@b29-tcrm-11-873] 26 open-surgery studies published from 1987 to 2010 were compared with 12 studies of either endoscope-assisted or fully endoscopic resection of cranial base chordomas from 2002 to 2010. No survival data were available for the endoscopic cohort, and follow-up for this latter group was limited to 18.5 months. The reported rate of complete resection was 61.0%, although the rate of petrous involvement and dural invasion was lower in the endoscopic group. The main limitation of this technique remains the risk of cerebrospinal fluid leakage and meningitis, largely mitigated by meticulous layered closure and vascularized mucosal flaps. Nevertheless, the risk in all recently published larger (n\>10) series with an intradural tumor component remains significant: 8%--33% developed cerebrospinal fluid leakage and 0%--14% meningitis.[@b19-tcrm-11-873],[@b20-tcrm-11-873],[@b23-tcrm-11-873],[@b30-tcrm-11-873]

Radiotherapy
------------

Although radiotherapy is an important therapeutic adjunct for cranial base chordomas, issues regarding both the timing of adjuvant radiotherapy, specifically after complete resection or only for residual/recurrent disease, and optimal type of radiotherapy are largely unresolved in the literature. Two recent meta-analyses based on the SEER database failed to demonstrate a benefit in survival in patients who received radiotherapy;[@b31-tcrm-11-873],[@b32-tcrm-11-873] however, this was possibly due to a number of sources of error, including but not limited to not controlling for the presence or absence of postoperative residual disease, histologic subtype, tumor size, patient age, type and dose of radiotherapy, era of treatment, and other factors. The difficulty of answering these questions is evident, and the following discussion attempts to interpret the available literature as much as possible.

There is significant heterogeneity in the literature regarding the use of adjuvant radiotherapy following surgical resections described as "complete" or "gross total". In one meta-analysis, among patients reported to have gross total resection of a skull-base chordoma, only 37.9% of patients were referred for adjuvant radiation therapy.[@b11-tcrm-11-873] Despite gross total resection, however, the recurrence rate following surgical removal of skull-base chordomas can be high. The results of large surgical series show a 5-year PFS of 22.5%--74.2% with complete upfront resection, and pooled numbers are too small to assess the benefit of radiotherapy in this subgroup.[@b11-tcrm-11-873] The concept of gross total resection in cranial base chordoma is difficult to define or prove, given the challenge surgeons have in identifying and removing microscopic invasion adjacent to the tumor, and of assessing microscopic disease on postoperative imaging. Histopathologic studies of chordoma-growth patterns point to an infiltrative propensity to invade bone and submucous tissue and along the loose connective tissue among local vessels, nerves, and muscles in multilayers or multilobular fashion.[@b33-tcrm-11-873] Chordomas lack a fibrous capsule,[@b34-tcrm-11-873] and tumor cells clearly invade intralesional fibrous septa, particularly in advanced stages of the disease. The rationale for adjuvant radiation therapy in light of these features is thus to improve local control.[@b13-tcrm-11-873]

Despite this, the evidence supporting the use of radiation therapy following complete surgical removal is mixed.[@b35-tcrm-11-873] In one large series of cranial base chordomas in which aggressive microsurgical resection was performed,[@b36-tcrm-11-873] 53 of 74 (71.6%) patients had complete resection either after single- or multistage resection. Only patients with gross residual disease received adjuvant radiation therapy. Five-year recurrence-free survival was 47%. In a larger updated series by the same authors,[@b37-tcrm-11-873] a trend toward routine adjuvant radiation therapy was observed, despite a similar rate of complete resection in early (1988--1999) and late (2000--2011) treatment eras. Five-year recurrence-free survival in the early and late-treatment eras was not statistically different: 55% and 59%, respectively. Five-year OS, however, was significantly better in the latter treatment era (93% vs 64%). Although there was a modest reduction in perioperative complications in the latter era, it is also conceivable that the improvement in survival may also at least in part be attributable to more routine use of adjuvant radiotherapy. This remains to be proven, however, in a comparative prospective fashion.

In addition to the timing of adjuvant radiotherapy, the optimal type of contemporary radiotherapy is controversial and as-yet unproven in the literature. Chordomas exhibit an increased dose--response relationship relative to other tumors.[@b38-tcrm-11-873] Therefore, the principal challenge of delivering safe and effective radiation therapy is to achieve clinically relevant doses while mitigating toxicity to adjacent neurovascular structures, such as the optic and other cranial nerves, pituitary gland, and brain stem. Proton-beam therapy has classically been considered to be well-suited for chordomas, due to its unique radiobiological properties,[@b39-tcrm-11-873] although evidence regarding its clinical superiority over other modern delivery techniques (eg, radiosurgery and fractionated stereotactic radiotherapy), radiation sources, and dose schedules has been questioned.[@b40-tcrm-11-873] To date, in addition to proton-beam radiotherapy, fractionated photon radiotherapy, CyberKnife and gamma-knife radiosurgery, and carbon-ion radiotherapy have all been reported for cranial base chordomas. Superiority of one radiotherapy modality over another has yet to be demonstrated, although large cohort comparisons are lacking. A discussion of each form of radiotherapy used currently for cranial base chordomas follows.

Charged heavy-particle therapy, such as with protons, takes advantage of a number of physical properties to deliver a high dose of radiation to tumors, while sparing falloff exposure to surrounding tissues. For cranial base chordomas, 5-year recurrence-free survival using proton-based therapy ranges from 59% to 73%.[@b39-tcrm-11-873],[@b41-tcrm-11-873],[@b42-tcrm-11-873] Amichetti et al performed a systematic review of the literature comparing proton-based radiotherapy with other available forms of radiation therapy for skull-base chordomas.[@b43-tcrm-11-873] There were no direct comparative studies, and the results of seven proton-beam therapy series including 416 patients were reviewed along with ten studies and 191 patients who underwent conventional forms of photon-based treatment. Mean dose delivery for proton-beam therapy was 66--83 cobalt gray equivalent. The average 5-year local control and OS were 69.2% and 79.8%, respectively. Only one study reported 10-year recurrence free survival and OS, which was 54%.[@b39-tcrm-11-873] This was found to be superior to conventional photon radiotherapy, which had 33.5% and 53.5% average local control and OS at 5 years, respectively. The years of treatment for the photon group were from 1938 to 2005, and significantly earlier than included proton-beam studies.

Carbon-ion radiotherapy exerts similar physical characteristics as proton-based treatment, but with higher relative biological effectiveness, which is of interest in relatively radio-resistant tumors, such as chordomas.[@b44-tcrm-11-873]--[@b50-tcrm-11-873] Early series from carbon-ion facilities in Germany and Japan have reported 3-year recurrence-free survival of 70%--80.6% for skull-base chordomas.[@b44-tcrm-11-873],[@b47-tcrm-11-873] A single-center randomized clinical trial of proton- versus carbon-radiation therapy in patients with cranial base chordomas is ongoing,[@b48-tcrm-11-873] although other preliminary data for sacral chordomas suggest a lack of difference in clinical efficacy between ion type.[@b49-tcrm-11-873] The primary disadvantages of proton and carbon ion-based radiotherapy are global availability and investment cost.[@b50-tcrm-11-873]

The results of more modern studies of fractionated photon-based radiotherapy for skull-base chordomas appears closer to proton-based therapy compared to earlier studies. Techniques are nevertheless variable from one study to another, including whether photon therapy is administered alone or in combination with particle therapy.[@b51-tcrm-11-873],[@b52-tcrm-11-873] In a recent small series of fractionated photon-based radiotherapy,[@b53-tcrm-11-873] 5-year OS was 76.4%, and 37.5% of patients were free of progression at 5 years. All patients either had gross residual disease after surgery or were being treated for symptomatic recurrences, however. Similar results were obtained by Debus et al[@b54-tcrm-11-873] who treated 37 patients with chordomas of the skull base or upper cervical spine. Local control was 50% and OS 82% at 5 years. In places where proton-beam or carbon-ion radiotherapy centers are not available, photon-based radiotherapy appears to confer grossly similar local control rates, although true comparative studies would be of great interest.

Smaller volume tumors have also been amenable to stereotactic radiosurgery (SRS), and early results have suggested comparable outcomes to other radiation modalities for residual or recurrent cases.[@b55-tcrm-11-873] SRS has been shown to be valuable in treating small residual postoperative and recurrent chordomas.[@b56-tcrm-11-873] Krishnan et al and Kano et al reported that using an SRS boost (15.0 Gy median margin dose) with or without fractionated radiation therapy (50.4 Gy median margin dose), the 5-year tumor-control rate was 55% and 65%, respectively.[@b55-tcrm-11-873],[@b57-tcrm-11-873] Liu et al and Hasegawa et al had a 5-year treated tumor-control rate of 66% and 72% when using 12.7 Gy and 15 Gy median margin dose, respectively. In both series, OS was 80% and 84% at 5 years, respectively.[@b58-tcrm-11-873],[@b59-tcrm-11-873] In a multicenter study of 71 patients who underwent gamma-knife SRS for chordomas, an 80% 5-year actuarial OS and 66% treated tumor-control rate after SRS was reported for the combined cohort. In this study, the median patient age was 45 years, the median SRS target volume was 7.1 cm^3^, and the median tumor-margin dose was 15.0 Gy.[@b56-tcrm-11-873]

Irrespective of the type of radiotherapy administered, a number of factors have been identified that may influence the response rate of radiotherapy. These include age, sex, tumor heterogeneity, extent of resection, presence of necrosis in the pretreatment biopsy, elevated tumor volume, and radiotherapy dose delivered.[@b60-tcrm-11-873],[@b61-tcrm-11-873] Among cases with subtotal resection, a residual tumor volume under 25--30 cm^3^ appears associated with better local control using adjunctive radiation therapy.[@b29-tcrm-11-873],[@b41-tcrm-11-873],[@b42-tcrm-11-873],[@b62-tcrm-11-873] In one study of 42 patients with skull-base chordomas, a gross tumor volume ≤25 mL was associated with excellent local control using spot-scanning-based proton radiotherapy.[@b63-tcrm-11-873] The typical at-risk structures during dosimetric planning include the optic apparatus, pituitary gland, and brain stem, and need to be carefully mapped pretreatment.

Investigation of novel therapeutic targets
==========================================

Despite the challenges posed by the rarity of chordoma, advances in the molecular understanding of chordomas have led to the identification of promising targetable pathways and prognostic markers. These include brachyury, receptor tyrosine kinases (RTKs), and downstream pathways. [Figure 1](#f1-tcrm-11-873){ref-type="fig"} lists some of the known pathways implicated in the pathogenesis of chordoma and the accompanying table ([Table 1](#t1-tcrm-11-873){ref-type="table"}) lists the matched targeted therapeutics. Loss of chromosome 1p36, 9p loss of heterozygosity, and an elevated Ki67 proliferative index all correlate with aggressive behavior and shorter OS in skull-base chordomas.[@b64-tcrm-11-873],[@b65-tcrm-11-873] Additionally, loss of chromosome 1q, gain of 2p, and aberrant brachyury copy-number changes and subsequent protein expression are associated with disease recurrence.

The brachyury or *T* gene located on chromosome 6q27 encodes a developmentally regulated transcription factor essential for notochordal development and formation of posterior mesodermal elements.[@b65-tcrm-11-873],[@b66-tcrm-11-873] Normally silenced in postdevelopmental tissue, brachyury is aberrantly reexpressed at high levels in chordoma cells,[@b67-tcrm-11-873] providing a diagnostic adjunct in differentiating chordoma from other tumors with similar histology and geographical location.[@b68-tcrm-11-873],[@b69-tcrm-11-873] The impact of brachyury experimental gain and loss of function on increased and decreased cell proliferation, respectively, highlights its biological and functional importance for chordoma growth and progression.[@b70-tcrm-11-873]--[@b73-tcrm-11-873]

Several lines of evidence also suggest a causative role of brachyury overexpression in chordoma formation.[@b74-tcrm-11-873] A study of four familial chordoma cohorts identified recurrent germ-line duplication within chromosome 6q27, which contains the brachyury gene.[@b75-tcrm-11-873] However, the vast majority of chordoma patients lack a family history, and in these more common sporadic tumors, only 6.8% of patients (16 of 236) exhibited genomic amplification of brachyury.[@b70-tcrm-11-873],[@b76-tcrm-11-873],[@b77-tcrm-11-873] Therefore, aberrant overexpression of brachyury in the latter group is potentially related to epigenetic changes rather than genomic amplification.[@b76-tcrm-11-873] Also, a nonsynonymous single-nucleotide polymorphism or SNP (rs2305089) in brachyury is strongly associated with development of chordoma,[@b78-tcrm-11-873] as well as worse OS in spinal chordoma patients.[@b79-tcrm-11-873] Lastly, genomic copy-number status and subsequent protein expression of brachyury is associated with shorter PFS on a cohort of 37 skull-base chordomas.[@b65-tcrm-11-873] However, a separate study published in the same year found no prognostic value of brachyury expression in a cohort of spinal chordomas.[@b80-tcrm-11-873] Whether this represents inherent biological differences from tumors arising from the spine and skull base remains to be tested in additional studies.

Given the tight correlation between genomic aberrations of brachyury leading to its temporally aberrant reexpression in chordoma, brachyury may be considered to be a driver oncogene in chordoma.[@b65-tcrm-11-873],[@b70-tcrm-11-873],[@b71-tcrm-11-873] As mentioned earlier, brachyury gain- and loss-of-function experiments have further established its putative role in the malignant growth of chordoma. Enforced silencing of brachyury in the JHC7 and UCH-1 chordoma cell lines result in growth cessation, senescence, and differentiation.[@b70-tcrm-11-873],[@b71-tcrm-11-873] Approximately 81.1% of 37 skull-base chordomas were found to be immunopositive for brachyury protein expression, indicating its potential central role in regulating growth in the majority of skull-base chordomas.[@b65-tcrm-11-873] A potential mechanism by which brachyury may contribute to chordoma's malignant phenotype may involve an activating role in epithelial--mesenchymal transition (EMT). EMT represents a mechanism for normal developmental and tissue-repair mechanisms, but can also be co-opted in cancer development.[@b81-tcrm-11-873],[@b82-tcrm-11-873] EMT can mediate infiltrative and invasive behavior in tumor cells via the selective activation of "mesenchymal" genetic programs, such as expression of the *SNAIL* gene. This is relevant in chordomas, as recent evidence has highlighted brachyury-mediated SNAIL activation in these tumors.[@b71-tcrm-11-873],[@b74-tcrm-11-873]

In the absence of active therapeutic approaches that directly target brachyury, inactivation of downstream or interacting signaling pathways provides an alternative means to short-circuit its function. For instance, the extensive cross talk between brachyury and other progrowth signaling pathways is of therapeutic significance for targeting brachyury in chordoma. FGFR/MEK/ERK signal-transduction pathways appear to mediate downstream signaling of brachyury in chordomas.[@b83-tcrm-11-873] Interestingly, these same pathways appear to effect positive feedback back on brachyury, which makes components of the FGFR/MEK/ERK pathways and brachyury potential therapeutic targets. A different study highlights the interaction between brachyury and the EGFR signaling pathway.[@b73-tcrm-11-873]

Reexpression of brachyury exclusively in chordoma, and its role in driving cancer behavior, makes brachyury an attractive target for therapeutic intervention. Since the protein is not expressed in nonchordoma normal tissues, targeting of the brachyury protein, its function, and associated signal-transduction pathways proves a very attractive clinical option. Recent advancements in the field of tumor immunology have rekindled the interest in its incorporation in cancer treatment.[@b84-tcrm-11-873] The brachyury protein therefore represents a logical target for immunotherapy in chordoma, given its pivotal role in the initiation and progression of the disease.[@b69-tcrm-11-873],[@b85-tcrm-11-873]

Protein tyrosine kinases (PTKs) mediate phosphorylation of selected tyrosine residues, which results in functional activation of many proteins and plays a crucial role in cancer development.[@b86-tcrm-11-873] RTKs are specialized, transmembrane PTKs that mediate signaling via sampling of the external environment. RTKs are composed of extracellular domains that bind cognate environmental ligands and an intracellular domain that mediates the signaling event via dimerization and binding to other signaling molecules. Mutations and over-expression of RTKs, such as PDGFα and -β, EGFR, MET, and HER2/NEU are central to the development of many cancers; therefore, they are attractive targets of therapeutic intervention. Hyperactive RTKs not only result in growth proliferation but also other procancer "hallmarks", such as enhanced cell survival and angiogenesis, which together contribute to tumorigenesis.[@b87-tcrm-11-873]

A large proportion of chordomas demonstrate EGFR overexpression, which is associated with aggressive clinical behavior. In a single study, 69% of chordoma samples expressed EGFR and 40% display *EGFR* amplification.[@b88-tcrm-11-873] This is recapitulated in three other studies with a cumulative number of 79.6% (43 of 54) chordoma cases demonstrating EGFR expression.[@b89-tcrm-11-873]--[@b91-tcrm-11-873] Given these observations, and the efficacy of EGFR inhibitors gefitinib and erlotinib in large-cell lung adenocarcinoma patients with activating *EGFR* mutations,[@b92-tcrm-11-873] antibody-based blockade or pharmacologic inhibition of EGFR signaling in chordoma is a logical potential therapeutic option. Anecdotal reports of partial responses and clinical improvement in recurrent sacral and skull-base chordoma with adjuvant single-agent or combined EGFR antibody (cetuximab) and EGFR-specific (gefitinib or erlotinib) or broader-spectrum tyrosine-kinase inhibitors (lapatinib)[@b66-tcrm-11-873],[@b93-tcrm-11-873],[@b94-tcrm-11-873] suggest that inhibition of EGFR protein and the downstream signaling pathway might offer a reasonable therapeutic option for some chordoma patients. However, larger, more controlled studies are required to define more precisely the indications for treatment and efficacy.

The PDGF receptor (PDGFR) is another PTK expressed in chordoma. Although PDGFR promotes chordoma cell proliferation through activation of the PI3K/AKT, RAS/ERK, and STAT pathways,[@b95-tcrm-11-873] the PDGFRβ isoform is preferentially upregulated and localized in the stromal components of chordomas,[@b89-tcrm-11-873],[@b96-tcrm-11-873]--[@b98-tcrm-11-873] suggesting a role in providing a supportive tumor microenvironment. Therefore, responses to PDGFR inhibition may reflect the relative abundance of tumor-associated stromata. In practice, the PDGFR preferential PTK inhibitor imatinib has demonstrated modest activity in small uncontrolled case series[@b97-tcrm-11-873],[@b99-tcrm-11-873] of chordoma patients with advanced disease, prompting a Phase II trial of 56 patients that realized overall clinical benefit in 64% and stable disease in 70% of patients.[@b100-tcrm-11-873] Despite some success with PDGFR inhibition in chordoma, a majority of treated patients do not show decline in tumor size, which may reflect the inability of targeting PDGFR expressing stromal elements to effect cytologic reduction of neoplastic chordoma cells. The presence of a prominent demineralized matrix in chordoma is another factor that may limit drug delivery and underlie cases that show suboptimal response to any systemic therapy.[@b96-tcrm-11-873] These observations indicate the critical need to consider the role of the tumor microenvironment as a barrier to drug delivery when designing future treatment strategies.

Targeting PTKs in chordoma can be challenging, due to their multiplicity and functional redundancy. Strategies to address this challenge could include simultaneous inhibition of multiple activated PTKs or targeting common signaling pathways downstream of the PTKs. For instance, signaling from multiple RTKs, including EGFR and PDGFR, converges on the PI3K/AKT/mTOR pathway, which is in turn negatively regulated by the PTEN tumor suppressor. Components of the PI3K/AKT/mTOR pathway are activated,[@b95-tcrm-11-873],[@b101-tcrm-11-873],[@b102-tcrm-11-873] and PTEN is suppressed in chordoma-tumor samples,[@b103-tcrm-11-873] suggesting that inhibition of this pathway alone or in combination with PTK inhibitors could have therapeutic activity against chordoma. Preclinical experimental studies using inhibitors of mTORC1 (rapamycin), mTOR (MLN0128), and PI3K/AKT/mTOR (PI-103) support this approach,[@b101-tcrm-11-873],[@b103-tcrm-11-873],[@b104-tcrm-11-873] while the addition of the mTOR inhibitor to imatinib showed additional clinical benefit in patients with advanced imatinib-resistant chordomas.[@b99-tcrm-11-873] These preliminary results indicate the therapeutic potential of targeting downstream effectors of activated PTKs and their potential effectiveness in combination with other targeted therapies.

The rarity of skull-base chordomas limits not only the number of treatments that can be practically tested in clinical trials but also the statistical power required to identify meaningful differences in outcome. Therefore, the application of precision or personalized oncology based on the molecular profiling of aberrant pathways in individual patients holds great promise for advancing the treatment of chordoma patients.[@b105-tcrm-11-873] For example, a chordoma patient treated with rapamycin on the basis of aberrant mTOR-pathway signaling identified in molecular profiling of patient-derived cells resulted in a sixfold reduction in tumor-growth rate.[@b106-tcrm-11-873] Additional targets for chordoma therapy will emerge from ongoing efforts at molecular profiling. For example, in addition to the targets discussed earlier, proangiogenic pathways mediated by VEGFR-2 and iNOS with relevance to other cancers have been implicated in chordoma.[@b107-tcrm-11-873] In a small clinical series, combined use of erlotinib and bevacizumab, a humanized anti-VEGF antibody, led disease stabilization in three chordoma patients.[@b108-tcrm-11-873] Ultimately, the establishment of large and well-annotated databases will be crucial to realize the benefits of personalized chordoma therapy. As proposed for other cancers, ongoing iterative analysis of individual patient molecular profiles and treatment responses generated from these databases is expected to better inform therapeutic choices in a prospective fashion.

Conclusion
==========

Management of chordomas affecting the base of the skull remains challenging, although epidemiologic data suggest an improvement in survival and local control in more recent eras. Complete safe removal after initial diagnosis appears to improve survival relative to incomplete resection. Endoscopic endonasal approaches may be useful in achieving safe resection of those chordomas affecting the midline clivus. Multiple modalities of radiation therapy have been used for chordoma, and results in well-selected individuals are comparable. To date, no chemotherapeutic agent has formed part of the standard treatment of chordomas. Based on an increasing knowledge of the molecular pathogenesis of skull-base chordomas, a number of targeted therapies have been attempted, with modest results for recurrent cases. Future systemic treatments based on affected pathways and application of the principals of personalized oncology will hopefully reduce the burden of this rare tumor.
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Summary of targeted molecular agents trialed in skull-base chordomas

  Agent(s)                  Study                                    Mechanism of action   Type of study    N    Tumor location                                             Results                                                                                                                                           Comments
  ------------------------- ---------------------------------------- --------------------- ---------------- ---- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------
  Cetuximab and gefitinib   Hof et al[@b110-tcrm-11-873]             EGFR inhibitor        Case report      1    Sacral                                                     Partial response over 9 months                                                                                                                    
  Cetuximab and gefitinib   Lindén et al[@b93-tcrm-11-873]           EGFR inhibitor        Case report      1    Cervical                                                   Initial symptomatic improvement; partial response over 4 months                                                                                   
  Erlotinib                 Singhal et al[@b66-tcrm-11-873]          EGFR inhibitor        Case report      1    Sacral                                                     Initial symptomatic improvement; 30% reduction in tumor bulk at 3 months                                                                          
  Erlotinib                 Launay et al[@b94-tcrm-11-873]           EGFR inhibitor        Case report      1    Sacral                                                     Initial symptomatic improvement; partial response or stable metastatic disease at 12 months                                                       
  Lapatinib                 Stacchiotti et al[@b111-tcrm-11-873]     EGFR inhibitor        Phase II study   18   Sacral (n=12), clivus (n=2), and mobile spine (n=4)        Six of 18 (33.3%) partial response Seven of 18 (38.9%) stable disease PFS 6 months                                                                
  Imatinib                  Casali et al[@b97-tcrm-11-873]           PDGFR inhibitor       Case series      6    Sacral (n=5) and clival (n=1)                              Five of six (83.3%) symptomatic improvement; six of six (100%) had radiologic effect over weeks to months                                         
  Imatinib                  Stacchiotti et al[@b100-tcrm-11-873]     PDGFR inhibitor       Phase II study   56   Sacral (n=33), mobile spine (n=14), and skull base (n=9)   One of 50 (2%) with partial response, and 35 of 50 (70%) with stable disease at 6 months                                                          
  Rapamycin                 Stacchiotti et al[@b99-tcrm-11-873]      mTOR inhibitor        Case series      10   Sacral (n=9) and skull base (n=1)                          One of nine (33.3%) had partial response, seven of nine (77.8%) had stable disease, and one of nine (11.1%) had progressive disease at 3 months   Rapamycin used in combination with imatinib
  Rapamycin                 Ricci-Vitiani et al[@b106-tcrm-11-873]   mTOR inhibitor        Case report      1    Skull base                                                 Sixfold decrease in tumor-growth rate over 10 months compared to pretreatment                                                                     
  Bevacizumab               Asklund et al[@b108-tcrm-11-873]         VEGF inhibitor        Case series      3    Sacral (n=1) and skull base (n=2)                          Stable disease over 4.5 years (n=1), 27 months (n=1), and 24 months (n=1)                                                                         Bevacizumab used in combination with erlotinib

**Abbreviation:** PFS, progression-free survival.
